021-51111890
购物车（）
sales@molnova.cn
Volasertib
CAS No. 755038-65-4
Volasertib ( BI 6727;BI-6727;BI6727 )
产品货号. M15871 CAS No. 755038-65-4
Volasertib (BI 6727) is a potent, selective Polo-like kinase (PLK) inhibitor with IC50 of 0.87, 5 and 56 nM for PLK1, 2 and 3, respectively.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥454 | 有现货 |
|
| 5MG | ￥753 | 有现货 |
|
| 10MG | ￥1337 | 有现货 |
|
| 25MG | ￥2349 | 有现货 |
|
| 50MG | ￥4236 | 有现货 |
|
| 100MG | ￥6148 | 有现货 |
|
| 500MG | ￥12798 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Volasertib
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Volasertib (BI 6727) is a potent, selective Polo-like kinase (PLK) inhibitor with IC50 of 0.87, 5 and 56 nM for PLK1, 2 and 3, respectively.
-
产品描述Volasertib (BI 6727) is a potent, selective Polo-like kinase (PLK) inhibitor with IC50 of 0.87, 5 and 56 nM for PLK1, 2 and 3, respectively; displays no inhibitory activity against a panel of >50 other kinases; inhibits proliferation of multiple cell lines derived from various cancer tissues, including HCT116 (EC50=23 nM) and NCI-H460 (EC50=21 nM),BRO (EC50=11 nM), and hematopoietic cancer cell HL-60 (EC50=32 nM); demonstrates marked antitumor activity in multiple cancer models, including a model of taxane-resistant colorectal cancer.Blood Cancer Phase 3 Clinical
-
同义词BI 6727;BI-6727;BI6727
-
通路Cell Cycle/DNA Damage
-
靶点PLK
-
受体PLK1
-
研究领域Cancer
-
适应症Blood cancer
化学信息
-
CAS Number755038-65-4
-
分子量618.81
-
分子式C34H50N8O3
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESO=C(N[C@H]1CC[C@@H](N2CCN(CC3CC3)CC2)CC1)C4=CC=C(NC(N=C5N(C(C)C)[C@@H]6CC)=NC=C5N(C)C6=O)C(OC)=C4
-
化学全称Benzamide, N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Rudolph D, et al. Clin Cancer Res. 2009 May 1;15(9):3094-102.
2. Grinshtein N, et al. Cancer Res. 2011 Feb 15;71(4):1385-95.
3. Schffski P, et al. Eur J Cancer. 2012 Jan;48(2):179-86.
4. Sanhaji M, et al. Cell Cycle. 2012 Feb 1;11(3):543-53.
2. Grinshtein N, et al. Cancer Res. 2011 Feb 15;71(4):1385-95.
3. Schffski P, et al. Eur J Cancer. 2012 Jan;48(2):179-86.
4. Sanhaji M, et al. Cell Cycle. 2012 Feb 1;11(3):543-53.
